VIFOR-PHARMA
18.9.2020 07:02:25 CEST | Business Wire | Press release
Regulatory News:
Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include:
- A purchase consideration of MCHF 435 for 100% of the share capital
- An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple
This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days.
OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years.
Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries and exporting to 60 countries worldwide, as a strategic partner. Optimus Holding is fully committed to the sustainable growth of OM Pharma and to invest considerably in R&D to become a global biotechnology company focused on improving the lives of patients with respiratory and inflammatory diseases.
Stefan Schulze, CEO of Vifor Pharma Group comments, “I am very pleased to have successfully completed the competitive sale process of OM Pharma announced earlier this year that was overseen by Rothschild & Co. Optimus Holding Ltd. brings a wealth of expertise and OM Pharma will benefit from the knowledge, financial investment and operational synergies of the new owners. This sale strengthens our strategic focus and will enable the company to further invest into our exciting product pipeline, especially in our core therapeutic area of nephrology.”
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viforpharma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005959/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Opensignal Crowns the World's Best 5G Networks29.9.2026 10:18:00 CEST | Press release
Annual Global 5G Awards Name Worldwide Winners, Leaders, And Rising Stars from Billions of Real-World User Experiences Opensignal, a global independent consumer connectivity analytics and insights company, today announced its annual Opensignal 5G Global Mobile Network Experience Awards, recognizing the providers delivering the best real-world 5G experiences across their national mobile networks. The awards assess billions of real-world user experiences across Download Speed, Video, Games, Voice App, Reliability, Coverage Experience, and — new for 2026 — Time on 5G, collected between Jan. 1 and June 29, 2026. "The consumer connectivity experience is at the core of everything we do at Opensignal. As the role of 5G in modern life grows, the bar for what great 5G looks like keeps rising," said Shawn Heidel, President, Network Experience at Opensignal. "The best operators in the world are defined by how well they deliver on that challenge, and this year's Global 5G Award winners set the sta
ClickHouse Expands Collaboration With Microsoft, Bringing Fabric Integration, Deeper OneLake Interoperability, and Enterprise Deployment Flexibility29.9.2026 09:30:00 CEST | Press release
ClickHouse, the company behind the open-source, real-time analytical database that has become the data layer for the AI era, today at The European Microsoft Fabric + SQL Community Conference announced a significant expansion of its strategic collaboration with Microsoft. The announcement encompasses four major milestones: the launch of the native ClickHouse workload for Microsoft Fabric, the general availability of OneLake read, the public preview of OneLake write, and the availability of ClickHouse Bring Your Own Cloud (BYOC) in the Microsoft Marketplace. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929947201/en/ ClickHouse expands collaboration with Microsoft This expansion builds on ClickHouse's growing presence within the Microsoft ecosystem, where data-intensive organizations rely on ClickHouse Cloud on Azure to power real-time observability, business intelligence, AI/ML pipelines, and analytical applications at sc
Opengear Expands Reach Through Pan-European Distribution Agreement with Ingram Micro29.9.2026 09:01:00 CEST | Press release
Opengear’s network resilience solutions now available across 20 European markets Opengear, a Digi International company (NASDAQ: DGII) and global leader in out-of-band management solutions, has signed its first pan-European distribution agreement with Ingram Micro, one of the world’s largest technology distributors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929668925/en/ Opengear Expands Reach Through Pan-European Distribution Agreement with Ingram Micro The agreement will give resellers in participating Ingram Micro countries access to Opengear’s portfolio, supported by Ingram Micro's regional infrastructure, logistics capabilities and partner network. This expands Opengear’s existing reach in the UK, Ireland, Spain, Germany, Italy, France, Belgium and Luxembourg, and brings its network resilience platform to resellers and end-users in additional European markets, such as Switzerland, Hungary, and Czech Republic. “T
Freemarket and Axiym launch LIQUI-DT™ – real-time business access to primary-market USD₮ from Tether29.9.2026 08:00:00 CEST | Press release
Freemarket and Axiym today launched a world-first service that gives businesses 24/7 real-time access to freshly minted, primary-market USD₮ issued by Tether. LIQUI-DTTM gives businesses compliant access to primary market stablecoins inside a fully regulated payment ecosystem via Freemarket’s global payment network. In audited trials, clients have minted or burned more than $300 million to date. Institutional users and high-volume traders will benefit from superior price certainty and direct liquidity giving them budgetary control. As the USD₮ is minted directly in the primary market, treasury and compliance teams have clear provenance for internal reporting 1. The LIQUI-DT service works because while no single party owns the whole stack, it is integrated into the Freemarket network. The combination of Freemarket’s compliant fiat rails and payment network, Axiym’s liquidity engine and on-chain settlement layer and Tether’s primary market issuance creates a regulated payments network wi
Estonia and Owkin Partner to Advance Sovereign AI in Biology29.9.2026 08:00:00 CEST | Press release
Estonia, led by the National Applied Research Center Metrosert, and Owkin today announced a collaboration to advance sovereign AI in biological and health research, working with Metrosert, Estonia’s state-owned applied research organisation. The collaboration will evaluate how K Pro, Owkin’s AI scientist platform, can help approved researchers work with complex Estonian health data inside secure national infrastructure, enabling reproducible analysis, and faster generation of scientific insight while preserving data sovereignty. The first phase will focus on selected Estonian health-data cohorts, with Owkin and Metrosert also exploring high-value research areas including oncology, where linked clinical, molecular, imaging and treatment-outcome data could support future biomedical research. Estonia has built one of the world’s most advanced digital public infrastructures and holds population-scale health and biomedical data assets. The partnership will explore how these foundations can
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom